Published in Lancet on March 29, 2008
1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain | NCT01844700
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry (2011) 5.46
The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull (2009) 4.69
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry (2013) 3.69
Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study. Am J Psychiatry (2014) 2.81
Mortality in schizophrenia: a measurable clinical endpoint. J Psychopharmacol (2010) 2.65
Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull (2010) 2.50
Early intervention in psychosis: concepts, evidence and future directions. World Psychiatry (2008) 2.17
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol (2011) 2.15
Cognitive remediation improves memory and psychosocial functioning in first-episode psychiatric out-patients. Psychol Med (2012) 2.07
Teaching trainees to negotiate research collaborations with industry: a mentorship model. Am J Psychiatry (2010) 2.04
Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis. Schizophr Bull (2011) 1.98
Effect of antipsychotic medication alone vs combined with psychosocial intervention on outcomes of early-stage schizophrenia: A randomized, 1-year study. Arch Gen Psychiatry (2010) 1.89
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry (2011) 1.87
Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (2009) 1.86
Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. Schizophr Bull (2009) 1.85
Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. Br J Psychiatry (2010) 1.76
Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology (2010) 1.67
Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry (2010) 1.65
Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization. J Clin Psychiatry (2012) 1.48
The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? Schizophr Bull (2010) 1.36
D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry (2010) 1.33
A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol (2011) 1.32
Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol (2011) 1.31
Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol (2012) 1.25
Are there modifiable risk factors which will reduce the excess mortality in schizophrenia? J Psychopharmacol (2010) 1.24
Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res (2008) 1.23
Antipsychotic drugs and obesity. Trends Mol Med (2010) 1.21
Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry (2012) 1.20
The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs (2014) 1.18
Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. BMC Psychiatry (2010) 1.16
Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophr Bull (2012) 1.14
Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry (2013) 1.12
Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers. Curr Psychiatry Rev (2012) 1.08
Packages of care for schizophrenia in low- and middle-income countries. PLoS Med (2009) 1.08
Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry (2011) 1.07
Management of antipsychotic-related weight gain. Expert Rev Neurother (2010) 1.07
A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry (2013) 1.03
Pharmacologic treatment of schizophrenia. Dialogues Clin Neurosci (2010) 1.02
Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review. Schizophr Res Treatment (2012) 1.00
The treatment of hallucinations in schizophrenia spectrum disorders. Schizophr Bull (2012) 1.00
Implementing Coordinated Specialty Care for Early Psychosis: The RAISE Connection Program. Psychiatr Serv (2015) 0.99
Pro-/anti-inflammatory dysregulation in patients with first episode of psychosis: toward an integrative inflammatory hypothesis of schizophrenia. Schizophr Bull (2013) 0.98
Amisulpride versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (2010) 0.98
The paradox of premature mortality in schizophrenia: new research questions. J Psychopharmacol (2010) 0.98
Comparative effectiveness research for antipsychotic medications: how much is enough? Health Aff (Millwood) (2009) 0.97
The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics. Schizophr Bull (2015) 0.96
Treatment Response in First-episode Schizophrenia. Clin Psychopharmacol Neurosci (2012) 0.95
Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry (2010) 0.94
The neurobiology and treatment of first-episode schizophrenia. Mol Psychiatry (2014) 0.93
Risk for antipsychotic-induced extrapyramidal symptoms: influence of family history and genetic susceptibility. Psychopharmacology (Berl) (2010) 0.93
Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia. BMC Psychiatry (2009) 0.93
Effectiveness as an outcome measure for treatment trials in psychiatry. World Psychiatry (2009) 0.93
Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months? J Clin Psychiatry (2011) 0.92
Pharmacogenetics of antipsychotic-induced side effects. Dialogues Clin Neurosci (2009) 0.92
Beyond the usual suspects: positive attitudes towards positive symptoms is associated with medication noncompliance in psychosis. Schizophr Bull (2012) 0.91
Olanzapine compared to quetiapine in adolescents with a first psychotic episode. Eur Child Adolesc Psychiatry (2009) 0.90
Metabolic syndrome in schizophrenia: Differences between antipsychotic-naïve and treated patients. J Pharmacol Pharmacother (2013) 0.89
Unmet needs in the management of schizophrenia. Neuropsychiatr Dis Treat (2014) 0.88
Treatment of neurolept-induced tardive dyskinesia. Neuropsychiatr Dis Treat (2013) 0.88
Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study. World J Biol Psychiatry (2010) 0.87
Going beyond "trial-and-error" in psychiatric treatments: OPTiMiSE-ing the treatment of first episode of schizophrenia. Schizophr Bull (2015) 0.87
Recent advances in treating cognitive impairment in schizophrenia. Psychopharmacology (Berl) (2008) 0.87
Patients' and clinicians' attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis. Ther Adv Psychopharmacol (2013) 0.86
Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial. Schizophr Bull (2009) 0.86
Profile of blonanserin for the treatment of schizophrenia. Neuropsychiatr Dis Treat (2013) 0.86
Schizophrenia--time to commit to policy change. Schizophr Bull (2014) 0.86
Cardiometabolic risk indicators that distinguish adults with psychosis from the general population, by age and gender. PLoS One (2013) 0.86
Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties. Patient Prefer Adherence (2012) 0.85
Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics. BMC Psychiatry (2011) 0.85
Aripiprazole versus haloperidol treatment in early-stage schizophrenia. J Psychiatr Res (2010) 0.85
Cancer and schizophrenia: is there a paradox? J Psychopharmacol (2010) 0.84
Efficacy of lifestyle interventions in physical health management of patients with severe mental illness. Ann Gen Psychiatry (2011) 0.84
The interrelation of needs and quality of life in first-episode schizophrenia. Eur Arch Psychiatry Clin Neurosci (2011) 0.84
Current and emergent treatments for symptoms and neurocognitive impairment in schizophrenia. Curr Treat Options Psychiatry (2015) 0.83
Effectiveness of sulpiride in adult patients with schizophrenia. Schizophr Bull (2012) 0.83
Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs. Front Psychiatry (2012) 0.83
Cure or curse? Ambivalent attitudes towards neuroleptic medication in schizophrenia and non-schizophrenia patients. Ment Illn (2009) 0.83
Long-stay psychiatric patients: a prospective study revealing persistent antipsychotic-induced movement disorder. PLoS One (2011) 0.82
Antipsychotic adherence, switching, and health care service utilization among Medicaid recipients with schizophrenia. Patient Prefer Adherence (2010) 0.81
Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine. PLoS One (2013) 0.81
Peripheral endocannabinoid system dysregulation in first-episode psychosis. Neuropsychopharmacology (2013) 0.81
Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies. Eur Neuropsychopharmacol (2015) 0.81
Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis. Psychopharmacology (Berl) (2011) 0.81
Psychiatrists' perceptions of the clinical importance, assessment and management of patient functioning in schizophrenia in Europe, the Middle East and Africa. Ann Gen Psychiatry (2013) 0.80
Adherence to Antipsychotic Medication in Bipolar Disorder and Schizophrenic Patients: A Systematic Review. J Clin Psychopharmacol (2016) 0.80
Role of long-acting injectable second-generation antipsychotics in the treatment of first-episode schizophrenia: a clinical perspective. Schizophr Res Treatment (2012) 0.80
Effectiveness of maintenance treatments with atypical and typical antipsychotics in stable schizophrenia with early stage: 1-year naturalistic study. Psychopharmacology (Berl) (2011) 0.80
The effects of second-generation antipsychotics on food intake, resting energy expenditure and physical activity. Eur J Clin Nutr (2013) 0.80
Effectiveness of long-acting antipsychotics in clinical practice : 1. A retrospective, 18-month follow up and comparison between paliperidone palmitate, risperidone long-acting injection and zuclopenthixol decanoate. Ther Adv Psychopharmacol (2016) 0.80
Treatment engagement of psychotic patients with a mobile mental health unit in rural areas in Greece: a five-year study. Schizophr Res Treatment (2013) 0.80
Treatment of clozapine-associated weight gain: a systematic review. Eur J Clin Pharmacol (2015) 0.80
A potential role for adjunctive vitamin D therapy in the management of weight gain and metabolic side effects of second-generation antipsychotics. J Pediatr Endocrinol Metab (2011) 0.80
Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia. Neuropsychiatr Dis Treat (2010) 0.80
Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials. Int J Neuropsychopharmacol (2015) 0.80
Update on the management of symptoms in schizophrenia: focus on amisulpride. Neuropsychiatr Dis Treat (2009) 0.80
Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients. Psychopharmacology (Berl) (2011) 0.80
Cognitive remediation improves cognition and good cognitive performance increases time to relapse--results of a 5 year catamnestic study in schizophrenia patients. BMC Psychiatry (2013) 0.80
Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia. Psychopharmacology (Berl) (2012) 0.79
Compliance, persistence, costs and quality of life in young patients treated with antipsychotic drugs: results from the COMETA study. BMC Psychiatry (2013) 0.79
2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2013) 18.17
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet (2009) 12.44
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Severe hypoglycemia and risks of vascular events and death. N Engl J Med (2010) 8.54
Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation (2002) 7.25
The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet (2008) 6.72
Prognosis and prognostic research: validating a prognostic model. BMJ (2009) 6.54
A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms. N Engl J Med (2004) 6.26
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet (2010) 6.23
Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA (2007) 6.02
Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med (2015) 5.86
Impact of anesthesia management characteristics on severe morbidity and mortality. Anesthesiology (2005) 5.17
Cognitive outcome after off-pump and on-pump coronary artery bypass graft surgery: a randomized trial. JAMA (2002) 5.06
Two-year outcomes after conventional or endovascular repair of abdominal aortic aneurysms. N Engl J Med (2005) 5.02
Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA (2002) 4.91
Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA (2008) 4.83
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA (2013) 4.82
Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet (2009) 4.73
Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension (2003) 4.71
A comparison of on-pump and off-pump coronary bypass surgery in low-risk patients. N Engl J Med (2003) 4.52
Prognosis and prognostic research: what, why, and how? BMJ (2009) 4.46
Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med (2010) 4.42
Prognosis and prognostic research: application and impact of prognostic models in clinical practice. BMJ (2009) 4.38
Prognosis and prognostic research: Developing a prognostic model. BMJ (2009) 4.38
WPA guidance on how to combat stigmatization of psychiatry and psychiatrists. World Psychiatry (2010) 4.26
The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry (2013) 4.16
Long-term outcome of open or endovascular repair of abdominal aortic aneurysm. N Engl J Med (2010) 3.70
Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA (2012) 3.67
Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care (2008) 3.65
Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J (2005) 3.58
Advancing paternal age and autism. Arch Gen Psychiatry (2006) 3.58
Prevalence of frailty in community-dwelling older persons: a systematic review. J Am Geriatr Soc (2012) 3.48
Superresolution imaging using single-molecule localization. Annu Rev Phys Chem (2010) 3.30
The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil (2010) 3.20
Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol (2008) 3.15
Relation between blood pressure and vascular events and mortality in patients with manifest vascular disease: J-curve revisited. Hypertension (2011) 3.11
Genome-wide association study of alcohol dependence. Arch Gen Psychiatry (2009) 3.08
Risk prediction models: II. External validation, model updating, and impact assessment. Heart (2012) 3.05
Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab (2005) 2.89
Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet (2002) 2.85
Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med (2010) 2.82
Coffee, decaffeinated coffee, and tea consumption in relation to incident type 2 diabetes mellitus: a systematic review with meta-analysis. Arch Intern Med (2009) 2.79
Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker. Heart (2012) 2.76
Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet (2007) 2.65
Cognitive outcomes 7.5 years after angioplasty compared with off-pump coronary bypass surgery. Ann Thorac Surg (2013) 2.64
Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause (2006) 2.64
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry (2005) 2.62
2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press (2013) 2.62
Carotid intima-media thickness measurements in intervention studies: design options, progression rates, and sample size considerations: a point of view. Stroke (2003) 2.61
Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. Int J Neuropsychopharmacol (2007) 2.60
Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities. Schizophr Bull (2008) 2.59
Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry (2005) 2.58
Dietary phytoestrogens and breast cancer risk. Am J Clin Nutr (2004) 2.55
Estimating interaction on an additive scale between continuous determinants in a logistic regression model. Int J Epidemiol (2007) 2.54
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet (2012) 2.53
High dietary glycemic load and glycemic index increase risk of cardiovascular disease among middle-aged women: a population-based follow-up study. J Am Coll Cardiol (2007) 2.47
Alpha-blockers as medical expulsive therapy for ureteral stones. Cochrane Database Syst Rev (2014) 2.45
Combined anatomical and clinical factors for the long-term risk stratification of patients undergoing percutaneous coronary intervention: the Logistic Clinical SYNTAX score. Eur Heart J (2012) 2.43
Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens (2002) 2.42
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med (2007) 2.41
Missing covariate data in medical research: to impute is better than to ignore. J Clin Epidemiol (2010) 2.37
Thyroid hormone concentrations, disease, physical function, and mortality in elderly men. J Clin Endocrinol Metab (2005) 2.35
Self-measurement of blood pressure at home reduces the need for antihypertensive drugs: a randomized, controlled trial. Hypertension (2007) 2.33
Heart disease risk determines menopausal age rather than the reverse. J Am Coll Cardiol (2006) 2.32
Dietary fiber and blood pressure: a meta-analysis of randomized placebo-controlled trials. Arch Intern Med (2005) 2.30
Internal and external validation of predictive models: a simulation study of bias and precision in small samples. J Clin Epidemiol (2003) 2.28
Cognitive behavior therapy via the Internet: a systematic review of applications, clinical efficacy and cost-effectiveness. Expert Rev Pharmacoecon Outcomes Res (2012) 2.27
Reporting and methods in clinical prediction research: a systematic review. PLoS Med (2012) 2.26
Effect of moderate alcohol consumption on adiponectin, tumor necrosis factor-alpha, and insulin sensitivity. Diabetes Care (2004) 2.24
Spurious systolic hypertension in young adults; prevalence of high brachial systolic blood pressure and low central pressure and its determinants. J Hypertens (2006) 2.20
Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study: lessons learned. Circulation (2002) 2.18
Coronary collaterals: an important and underexposed aspect of coronary artery disease. Circulation (2003) 2.17
The effect of outpatient preoperative evaluation of hospital inpatients on cancellation of surgery and length of hospital stay. Anesth Analg (2002) 2.16
Meta-analyses identify 13 loci associated with age at menopause and highlight DNA repair and immune pathways. Nat Genet (2012) 2.12
Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: the PRISMA study. Arch Intern Med (2005) 2.11
Depressive symptoms in subjects with diagnosed and undiagnosed type 2 diabetes. Psychosom Med (2007) 2.09
Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int J Epidemiol (2010) 2.08
Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension (2011) 2.05
Measurement properties of the Groningen Frailty Indicator in home-dwelling and institutionalized elderly people. J Am Med Dir Assoc (2012) 2.02
Genome-wide association and genetic functional studies identify autism susceptibility candidate 2 gene (AUTS2) in the regulation of alcohol consumption. Proc Natl Acad Sci U S A (2011) 2.01
In-hospital morbidity and mortality due to severe malarial anemia in western Kenya. Am J Trop Med Hyg (2007) 1.99
Aortic stiffness is associated with atherosclerosis of the coronary arteries in older adults: the Rotterdam Study. J Hypertens (2006) 1.98
Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol (2005) 1.96
Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol (2013) 1.96
Estimating measures of interaction on an additive scale for preventive exposures. Eur J Epidemiol (2011) 1.94
Carotid intima-media thickness and coronary atherosclerosis: weak or strong relations? Eur Heart J (2007) 1.94
Association of the ER22/23EK polymorphism in the glucocorticoid receptor gene with survival and C-reactive protein levels in elderly men. Am J Med (2004) 1.93
A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophr Res (2006) 1.93
Cognitive function across the life course and the menopausal transition in a British birth cohort. Menopause (2006) 1.92
Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation (2008) 1.91
Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry (2010) 1.90